Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr;13(2):100-108.
doi: 10.1007/s11899-018-0442-1.

Recent Developments in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia

Victor M Orellana-Noia  1 , Michael G Douvas  2   3
Affiliations
Review

Recent Developments in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia

Victor M Orellana-Noia et al. Curr Hematol Malig Rep. 2018 Apr.

Abstract

Purpose of review: Adolescent and Young Adult (AYA) Oncology is a relatively new field encompassing research in the unique pathophysiology, clinical care, and psychosocial issues facing patients between the ages of 15 and 40 with cancer. About 100,000 of the approximately 1.5 million people diagnosed annually with cancer in the USA are in this age range. This chapter will review notable new developments in the care of adolescents and young adults with acute lymphoblastic leukemia (ALL) within the last 3 years.

Recent findings: The preponderance of data favors the treatment of AYA ALL patients with pediatric-inspired treatment regimens due to better relapse-free and overall survival. Minimal residual disease (MRD) measurement is emerging as an important prognostic factor and can serve as a new measure of efficacy of the addition of novel therapies to the treatment of patients with new diagnoses. There have been several treatment advances ranging from new cytotoxic agents for ALL to new antibody-based therapy to novel immune therapies such as CAR-T cells. The care of AYA ALL patients is improving as the unique issues for this patient population are addressed.

Keywords: Acute lymphoblastic leukemia; Adolescent and Young Adult (AYA); Augmented BFM treatment; Minimal residual disease (MRD); Novel therapy; Ph-like ALL.

PubMed Disclaimer

References

    1. Br J Haematol. 2016 Feb;172(3):439-51 - PubMed
    1. J Clin Oncol. 2017 Jun 1;35(16):1795-1802 - PubMed
    1. Blood. 2017 Jul 27;130(4):440-452 - PubMed
    1. N Engl J Med. 2014 Oct 16;371(16):1507-17 - PubMed
    1. J Clin Oncol. 2014 Dec 20;32(36):4134-40 - PubMed

LinkOut - more resources